Skip to main content

Acorda Therapeutics, Inc.

ACORDelisted Apr 25, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001008848

Acorda Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Jun 23, 2023; 17 institutions reported holding it in 13F filings for Q1 2024, worth $2.13M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Acorda Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Acorda Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Acorda Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Panem Sandra PhDDirector–Jun 23, 20230
Kelley John PDirector–Jun 23, 20230
Varian JohnDirector–Jun 23, 20230
Jensen PederDirector–Jun 23, 20230
Burns Thomas M.Director–Jun 23, 20230
Cohen RonPresident and CEO149,757Apr 4, 20230
Belloff Neil S.General Counsel and Corp Secy–Apr 4, 20230
Clem Kerry MChief Commercial Officer10,083Apr 4, 20230
Sabella Lauren MChief Operating Officer10,710Sep 7, 20220
Randall LorinDirector–Jun 14, 20220
Gesser Michael AChief Financial Officer–Nov 9, 20210
Morales RobertInterim PAO & PFO4,423Sep 8, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 20, 2023 (view filing)Mar 16-174 daysCohen RonPresident and CEOPPurchase+20.2K$0.6248+$12.6K+15.6%149.8K after2 lots
Mar 21, 2022 (view filing)Mar 174 daysCohen RonPresident and CEOSSale−2.29K$1.70−$3.89K−1.7%129.6K after